Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 62 PAGES: 294

The report provides data on the Valeant Pharmaceuticals International, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Valeant Pharmaceuticals International, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Valeant Pharmaceuticals International, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									  Valeant Pharmaceuticals International, Inc. – Product
               Pipeline Review – 2012

                                                                                          Reference Code: GMDHC02240CDB
                                                                                                 Publication Date: MAY 2012




Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012              GMDHC02240CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures .............................................................................................................................................................................. 11
Valeant Pharmaceuticals International, Inc. Snapshot ..................................................................................................................... 12
    Valeant Pharmaceuticals International, Inc. Overview................................................................................................................. 12
    Key Information ........................................................................................................................................................................... 12
    Key Facts..................................................................................................................................................................................... 12
Valeant Pharmaceuticals International, Inc. – Research and Development Overview ..................................................................... 13
    Key Therapeutic Areas ................................................................................................................................................................ 13
Valeant Pharmaceuticals International, Inc. – Pipeline Review ........................................................................................................ 16
    Pipeline Products by Stage of Development ............................................................................................................................... 16
    Pipeline Products – Monotherapy ............................................................................................................................................... 17
Valeant Pharmaceuticals International, Inc. – Pipeline Products Glance ......................................................................................... 18
    Valeant Pharmaceuticals International, Inc. – Late Stage Pipeline.............................................................................................. 18
        Registration Filed Products/Combination Treatment Modalities.............................................................................................. 18
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 19
    Valeant Pharmaceuticals International, Inc. Clinical Stage Pipeline Products ............................................................................. 20
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 20
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 21
Valeant Pharmaceuticals International, Inc. – Drug Profiles ............................................................................................................. 22
    IDP 113 ....................................................................................................................................................................................... 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    IDP 115 ....................................................................................................................................................................................... 23
        Product Description................................................................................................................................................................. 23
        Mechanism of Action ............................................................................................................................................................... 23
        R&D Progress ......................................................................................................................................................................... 23
    IDP-107 ....................................................................................................................................................................................... 24
        Product Description................................................................................................................................................................. 24
        Mechanism of Action ............................................................................................................................................................... 24
        R&D Progress ......................................................................................................................................................................... 24
    IDP-108 ....................................................................................................................................................................................... 25
        Product Description................................................................................................................................................................. 25
        Mechanism of Action ............................................................................................................................................................... 25
        R&D Progress ......................................................................................................................................................................... 25
    IDP-109 ....................................................................................................................................................................................... 26
        Product Description................................................................................................................................................................. 26
        Mechanism of Action ............................................................................................................................................................... 26
        R&D Progress ......................................................................................................................................................................... 26
    IDP-118 ....................................................................................................................................................................................... 27
        Product Description................................................................................................................................................................. 27



Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012                                                           GMDHC02240CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review



        Mechanism of Action ............................................................................................................................................................... 27
        R&D Progress ......................................................................................................................................................................... 27
    Taribavirin .................................................................................................................................................................................... 28
        Product Description................................................................................................................................................................. 28
        Mechanism of Action ............................................................................................................................................................... 28
        R&D Progress ......................................................................................................................................................................... 28
    Trobalt ......................................................................................................................................................................................... 30
        Product Description................................................................................................................................................................. 30
        Mechanism of Action ............................................................................................................................................................... 30
        R&D Progress ......................................................................................................................................................................... 30
Valeant Pharmaceuticals International, Inc. – Pipeline Analysis ...................................................................................................... 32
    Valeant Pharmaceuticals International, Inc. – Pipeline Products by Therapeutic Class .............................................................. 32
    Valeant Pharmaceuticals International, Inc. – Pipeline Products By Target ................................................................................ 34
    Valeant Pharmaceuticals International, Inc. – Pipeline Products by Route of Administration ...................................................... 35
    Valeant Pharmaceuticals International, Inc. – Pipeline Products By Mechanism of Action ......................................................... 36
Valeant Pharmaceuticals International, Inc. – Recent Pipeline Updates ......................................................................................... 37
Valeant Pharmaceuticals International, Inc. - Dormant Projects....................................................................................................... 39
Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products ................................................................................. 40
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 40
        BVF-045 .................................................................................................................................................................................. 40
        BVF-146 .................................................................................................................................................................................. 40
        BVF-324 .................................................................................................................................................................................. 41
        RUS-350 ................................................................................................................................................................................. 41
        Taribavirin ............................................................................................................................................................................... 41
        Tetrabenazine ......................................................................................................................................................................... 41
        Tiazole .................................................................................................................................................................................... 41
Valeant Pharmaceuticals International, Inc. – Company Statement ................................................................................................. 42
Valeant Pharmaceuticals International, Inc. – Locations And Subsidiaries ...................................................................................... 47
    Head Office.................................................................................................................................................................................. 47
    Other Locations & Subsidiaries ................................................................................................................................................... 47
Valeant Pharmaceuticals International, Inc. - Key Manufacturing Facilities ..................................................................................... 52
Valeant Pharmaceuticals International, Inc., Recent Developments ................................................................................................ 53
    Valeant Pharmaceuticals International, Inc.- Press Release ....................................................................................................... 53
        Feb 15, 2012: FDA Approves Additional Manufacturer For Valeant's Methoxsalen ................................................................ 53
        Nov 02, 2009: GlaxoSmithKline and Valeant Pharmaceuticals files a New Drug Application with FDA For Retigabine ......... 53
        Jun 22, 2009: Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine ............................................ 53
        Jun 02, 2009: Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study ..................... 54
        May 18, 2009: Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine ............................................................ 54
        Apr 07, 2009: Biovail Announces U.S. Availability of Aplenzin(TM) Tablets ........................................................................... 55
        Jan 13, 2009: S&R Communications Group Partners With Ovation Pharmaceuticals to Launch Xenazine (tetrabenazine) .. 56
Financial Deals Landscape .............................................................................................................................................................. 57
    Valeant Pharmaceuticals International, Inc., Deals Summary ..................................................................................................... 57
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deal Details .............................................................. 68
    Asset Transactions ...................................................................................................................................................................... 68


Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012                                                             GMDHC02240CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                        Page(3)
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review



        Valeant Pharma To Acquire AcneFree And Certain Assets From University Medical............................................................. 68
        Valeant Pharma To Acquire Generic Drugs From Atlantis Pharma For $71 Million ................................................................ 70
        Valeant Pharma International To Acquire Branded Generic Products Portfolio From Gerot Lannach .................................... 72
        Fleming Pharma Sells Four Products Rights To Valeant International (Barbados) ................................................................. 74
        Biovail Labs Acquires US And Canadian Rights To Zovirax From GlaxoSmithKline .............................................................. 76
        Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme ................................................................................ 78
        Biovail Labs Acquires Two Australian Skin Care Brands From Hamilton................................................................................ 80
        Valeant Acquires Manufacturing Plant In Brazil ...................................................................................................................... 82
        Aton Pharma Acquires Marketing Rights For LODOSYN From Bristol-Myers ........................................................................ 83
        Valeant Pharma Acquires Polish Dermatological Products ..................................................................................................... 85
        Biovail Acquires AMPAKINE Compounds From Cortex Pharma ............................................................................................ 86
        Valeant Pharma Acquires Income Rights Of Clindamycin And Benzoyl Peroxide Gel............................................................ 89
        Biovail Acquires Rights Of Tetrabenazine And Related Assets From Cambridge Labs .......................................................... 90
        Biovail Acquires US Rights Of Wellbutrin XL From GlaxoSmithKline...................................................................................... 92
        Valeant Pharma Acquires Rights Of Nabilone From Cambridge Labs .................................................................................... 94
        Valeant Pharma Acquires Argentina Product Rights Of Melleril From Novartis ...................................................................... 96
        Valeant Pharma Acquires Rights Of Hep-C Drug Infergen From InterMune ........................................................................... 97
        Valeant Pharma Acquires Product Rights Of Melleril From Novartis ...................................................................................... 99
        Valeant Pharma Acquires European Union Rights Of Tasmar From Roche ......................................................................... 101
        Valeant Pharma Acquires Non-European Union Rights Of Tasmar From Roche ................................................................. 103
    Private Equity ............................................................................................................................................................................ 105
        Amber Trust Acquires Minority Stake In Sanitas ................................................................................................................... 105
        Citigroup Venture Capital Acquires Minority Stake In Sanitas............................................................................................... 106
    Partnerships .............................................................................................................................................................................. 107
        Valeant International Enters Into Distribution Agreement With Sanofi For Zuacta ................................................................ 107
        Valeant Pharma Enters Into Co-Marketing Agreement With Spear Pharma ......................................................................... 108
        bioskin Forms Joint Venture With Cu-Tech ........................................................................................................................... 109
        Biovail Enters Into Marketing And Distribution Agreement With sanofi-aventis .................................................................... 110
        Valeant Pharma Enters Into Agreement With GlaxoSmithKline ............................................................................................ 111
        Valeant Pharma Enters Into Joint Venture With Meda .......................................................................................................... 114
        Aton Pharma Enters Into Distribution Agreement With Meizler Biopharma .......................................................................... 115
        Biovail Enters Into Co-marketing Agreement With Janssen Pharmaceutica ......................................................................... 116
        Valeant Pharma Enters Into Co-Promotion Agreement With Ascend Therapeutics .............................................................. 117
        Biovail Enters Into Agreement With Depomed ...................................................................................................................... 118
        JSJ Pharma Enters Into Co-Marketing Agreement With Valeant Pharma ............................................................................ 119
        Sciele Pharma Enters Into Agreement With Biovail .............................................................................................................. 120
        Valeant Pharma Enters Into Co-Marketing Agreement With Intendis ................................................................................... 122
        Biovail Enters Into Agreement With Novartis Pharma Canada ............................................................................................. 123
        Biovail Pharma Enters Into Co-Promotion Agreement With AstraZeneca Pharma ............................................................... 125
        Biovail Amends Its Agreement With Depomed ..................................................................................................................... 126
        Biovail Enters Into Distribution Agreement With Teva Pharma ............................................................................................. 127
        Biovail Pharma Enters Into Co-Marketing Agreement With Ortho-McNeil ............................................................................ 128
        Par Pharma Enters Into Co-Promotion Agreement With Valeant Pharma ............................................................................ 129
        Medpointe Enters Into Co-Promotion Agreement With Biovail .............................................................................................. 130


Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012                                                         GMDHC02240CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                   Page(4)
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review



        Valeant Pharma Enters Into Co-Marketing Agreement With Allergan ................................................................................... 131
        Biovail Enters Into A Research Agreement With Kos Pharma .............................................................................................. 138
        Alliance Pharma Enters Into Co-Promotion Agreement With Valeant Pharma ..................................................................... 139
        Valeant Pharma Enters Into Co-Promotion Agreement With Caleel + Hayden ..................................................................... 141
    Licensing Agreements ............................................................................................................................................................... 142
        Biovail Enters Into An Agreement With Pharma Pass........................................................................................................... 142
        Biovail Enters Into Licensing And Development Agreement For BVF-324............................................................................ 144
        Teva Pharma Enters Into Licensing Agreement With Biovail ................................................................................................ 145
        Senetek Amends Licensing Agreement With Valeant Pharma ............................................................................................. 146
        Depomed Amends Licensing Agreement With Biovail .......................................................................................................... 147
        Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese.......................................................... 148
        Promius Pharma Enters Into Licensing With Valeant Pharma For Cloderm Cream.............................................................. 150
        Biovail Labs Enters Into Licensing Agreement With Allergan For Aczone ............................................................................ 151
        Kadmon Pharma Enters Into Licensing Agreement With Valeant Pharma For Ribavirin ...................................................... 152
        Valeant Pharma Enters Into Licensing Agreement With Kadmon For Taribavirin ................................................................. 153
        Biovail Labs International Enters Into Licensing Agreement With Kyowa Hakko Kirin .......................................................... 154
        Alexza Pharma Enters Into Licensing Agreement With Biovail Labs .................................................................................... 156
        MedGenesis Therapeutix Enters Into Licensing Agreement With Biovail ............................................................................. 158
        Valeant Pharma Enters Into Licensing Agreement With Meda For Cesamet........................................................................ 159
        Valeant Pharma Enters Into Licensing Agreement With Meda For Dermatology Products................................................... 160
        Biovail Enters Into Licensing Agreement With Santhera ....................................................................................................... 161
        Penwest And Endo Pharma Enter Into Licensing Agreement With Valeant.......................................................................... 163
        Valeant Pharma Enters Into Option Licensing Agreement With Schering-Plough ................................................................ 165
        Biovail Enters Into Licensing Agreement With ACADIA Pharma........................................................................................... 167
        GlaxoSmithKline Enters Into Licensing Agreement With Valeant Pharma ............................................................................ 169
        Senetek Enters Into Licensing Agreement With Valeant Pharma For Kinetin And Zeatin..................................................... 171
        Valeant Pharma Enters into Licensing Agreement With Jazz Pharma.................................................................................. 173
        Schering-Plough Signs Licensing Agreement With Valeant Pharma And Metabasis Therapeutics For Pradefovir .............. 174
        Biovail Amends Development And Licensing Agreement With Ethypharm ........................................................................... 175
        Kaken Pharma Enters Into Licensing Agreement With Dow Pharma Sciences .................................................................... 176
        Senetek Enters Into Licensing Agreement With Valeant Pharma ......................................................................................... 177
        SkinMedica Expands Its Licensing Agreement With Dow Pharma Sciences ........................................................................ 178
        Lescarden Enters Into Licensing Agreement With Valeant Pharma...................................................................................... 180
    Equity Offering ........................................................................................................................................................................... 181
        Valeant Pharma Completes Public Offering Of $199 Million ................................................................................................. 181
    Debt Offering ............................................................................................................................................................................. 183
        Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For $950 Million ........ 183
        Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For $550 Million ........ 185
        Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For $650 Million.................. 187
        Valeant Pharma Completes Public Offering Of 6.875% Senior Unsecured Notes Due 2018 For $1,000 Million .................. 189
        Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2020 For $700 Million .................................. 191
        Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2017 For $500 Million .................................. 193
        Valeant Pharma Completes Private Placement Of Senior Unsecured Notes For $400 Million ............................................. 195
        Biovail Completes Private Placement Of Senior Convertible Notes For $350 Million ........................................................... 197


Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012                                                         GMDHC02240CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                   Page(5)
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review



        Valeant Pharma Completes Placement Of 8.375% Senior Notes For $365 Million .............................................................. 198
    Asset Transactions .................................................................................................................................................................... 200
        Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International............................ 200
        Ampio Pharma Completes Acquisition Of Rights Of Drug Delivery Technology From Valeant International ........................ 202
        Cortex Pharma Reacquires AMPAKINE Compounds From Biovail ...................................................................................... 204
        MDRNA Acquires Bridged Nucleic Acid Patents From Valeant Pharma ............................................................................... 206
        Meda Acquires European Business Operations Of Valeant Pharma .................................................................................... 207
        Valeant Pharma Sells Commercial Operations In Argentina................................................................................................. 209
        Invida Pharma Holdings Acquires Asia Pacific Operations From Valeant Pharma ............................................................... 210
        Three Rivers Acquires US And Canadian Rights Of Infergen From Valeant......................................................................... 212
        Legacy Pharma Acquires Two Manufacturing Facilities From Valeant Pharma .................................................................... 214
        Ardea Biosciences Acquires Intellectual Property And Other Assets From Valeant Pharma ................................................ 216
        Strides Acquires ICN Valeant Sterile Manufacturing Facility From Valeant Pharma ............................................................. 218
        Sun Pharma Industries Acquires Bryan Manufacturing Facility From Valeant Pharma......................................................... 219
        Sun Pharma Acquires Hungary Manufacturing Operations From Valeant Pharma............................................................... 221
        Alliant Pharma Acquires RONDEC From Biovail .................................................................................................................. 222
        Kos Pharma Acquires Distribution Rights To Cardizem From Biovail ................................................................................... 223
        Valeant Pharma Sells Manufacturing Facility In Mexico City ................................................................................................ 224
        LABIANA Pharma Acquires Manufacturing Operations From Valeant Pharma .................................................................... 225
        Shionogi USA Acquires Rights For CEDAX From Biovail Pharma........................................................................................ 226
        Chemoprojekt Acquires Czech Manufacturing Operations From Valeant Pharma................................................................ 227
    Acquisition ................................................................................................................................................................................. 228
        Valeant Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine .......
								
To top